Arvinas (ARVN) Stock Analysis & AI Equity Report
Arvinas (ARVN) overview
Arvinas (ARVN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 263m and operating profit of USD -119m; the year-end share price was 11.86 USD and market capitalisation was USD 753m. Arvinas is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arvinas's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Arvinas
Arvinas is a clinical-stage biotechnology company using its PROTAC platform to develop medicines that selectively degrade disease-associated proteins. Its clinical programs address oncology, neurodegenerative disease, and immuno-oncology, including candidates targeting BCL6, LRRK2, polyQ-AR, and HPK1. Vepdegestrant, developed with Pfizer and approved as VEPPANU, is licensed to Rigel, which holds global development, manufacturing, and commercialization rights.
Generate the Arvinas report
Arvinas is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Arvinas and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Arvinas
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.